Arrow Pharmaceuticals — Valpam 5
What are the defects?
One batch of Valpam 5 (batch CP218) may contain blister strips with a white Valpam 2mg tablet, instead of a yellow Valpam 5mg tablet.
What are the hazards?
Patients may not receive the correct dose.
What should consumers do?
If patients have Valpam 5 from batch number CP218, blister strips should be inspected prior to use, in order to ensure that all of the tablets in a given blister are light yellow in colour and marked with ‘DZ 5’ on one side. This marking will only be visible if the tablet happens to be loaded into the blister facing upwards, which is normal for all blistered tablets. In the event no anomalies are found, the product may continue to be used as normal and no further action is necessary. In the unlikely event a blister is found to contain a white‐to‐off white tablet amongst the other yellow tablets, these blisters are affected and should not be used. Consumers are advised to return any unopened affected blisters to the place of purchase for a refund or replacement.
Further information is available from https://www.tga.gov.au/alert/valpam-5-diazepam-5-mg-tablets or from Arrow Pharma on 1800 941 148.
- 1 March 2018 - 31 May 2018
Therapeutic Goods Administration is the responsible regulator for this recall.